Pediatric Melanoma-The Whole (conflicts of Interest) Story

Overview

Journal Int J Womens Dermatol

Publisher Wolters Kluwer

Date 2019 Apr 19

PMID 30997384

Citations 7

Authors

Klaus Rose

Jane M Grant-Kels

Affiliations

Soon will be listed here.

Citing Articles

Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.

Ettienne E, Russo E, Striano P, Grant-Kels J, Rose K World J Methodol. 2024; 14(2):92371.

PMID: 38983658 PMC: 11229878. DOI: 10.5662/wjm.v14.i2.92371.

Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation.

Jia C, Yang F, Li R Int J Gen Med. 2022; 15:379-391.

PMID: 35046701 PMC: 8761914. DOI: 10.2147/IJGM.S338890.

COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is Here.

Rose K, Grant-Kels J, Ettienne E, Tanjinatus O, Striano P, Neubauer D Rambam Maimonides Med J. 2021; 12(2).

PMID: 33780329 PMC: 8092959. DOI: 10.5041/RMMJ.10433.

Too Many Avoidable Suicides Occur Worldwide in Young Patients.

Rose K, Neubauer D, Grant-Kels J Rambam Maimonides Med J. 2019; 10(4).

PMID: 31545703 PMC: 6824826. DOI: 10.5041/RMMJ.10374.

The Challenges of Pediatric Drug Development.

Rose K Curr Ther Res Clin Exp. 2019; 90:128-134.

PMID: 31388368 PMC: 6677568. DOI: 10.1016/j.curtheres.2019.01.007.

References

Casanova M, Ozyar E, Patte C, Orbach D, Ferrari A, Veyrat-Follet C . International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol. 2015; 77(2):289-98. DOI: 10.1007/s00280-015-2933-2. View

Sun H, Temeck J, Chambers W, Perkins G, Bonnel R, Murphy D . Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned. Ther Innov Regul Sci. 2017; 2017:1-7. PMC: 5587157. DOI: 10.1177/2168479017725558. View

Tsukamoto K, Carroll K, Onishi T, Matsumaru N, Brasseur D, Nakamura H . Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks. Clin Ther. 2016; 38(3):574-81. DOI: 10.1016/j.clinthera.2016.01.012. View

Gaspar N, Marshall L, Binner D, Herold R, Rousseau R, Blanc P . Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol. 2018; 29(3):766-771. PMC: 5889024. DOI: 10.1093/annonc/mdy002. View

Fraser C, Brown P, Megason G, Ahn H, Cho B, Kirov I . Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability. J Pediatr Hematol Oncol. 2013; 36(4):e212-8. PMC: 4020582. DOI: 10.1097/MPH.0000000000000021. View

Eggen C, Durgaram V, van Doorn R, Mooi W, Pardo L, Pasmans S . Incidence and relative survival of melanoma in children and adolescents in the Netherlands, 1989-2013. J Eur Acad Dermatol Venereol. 2017; 32(6):956-961. DOI: 10.1111/jdv.14665. View

Dunne J, Rodriguez W, Murphy M, Beasley B, Burckart G, Filie J . Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011; 128(5):e1242-9. DOI: 10.1542/peds.2010-3487. View

Geukes Foppen M, Donia M, Svane I, Haanen J . Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol. 2015; 9(10):1918-35. PMC: 5528735. DOI: 10.1016/j.molonc.2015.10.018. View

Pappo A . Pediatric melanoma: the whole (genome) story. Am Soc Clin Oncol Educ Book. 2014; :e432-5. DOI: 10.14694/EdBook_AM.2014.34.e432. View

10.

Rose K, Muller T . Children with multiple sclerosis should not become therapeutic hostages. Ther Adv Neurol Disord. 2016; 9(5):389-95. PMC: 4994785. DOI: 10.1177/1756285616656592. View

11.

Hamowy R . The early development of medical licensing laws in the United States, 1875-1900. J Libert Stud. 1979; 3(1):73-119. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Siegfried E, Jaworski J, Eichenfield L, Paller A, Hebert A, Simpson E . Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry. Pediatr Dermatol. 2018; 35(3):303-322. DOI: 10.1111/pde.13452. View

14.

Falkner B . Monitoring and management of hypertension with obesity in adolescents. Integr Blood Press Control. 2017; 10:33-39. PMC: 5700763. DOI: 10.2147/IBPC.S125094. View

15.

Rose K, Happle R . The Effect of Regulation on Pediatric Psoriasis Drug Approvals: The Challenge of the European Union Pediatric Investigation Plans. Pediatr Dermatol. 2017; 34(3):e154-e159. DOI: 10.1111/pde.13097. View

16.

Vargesson N . Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015; 105(2):140-56. PMC: 4737249. DOI: 10.1002/bdrc.21096. View

17.

Pasquali S, Burstein D, Benjamin Jr D, Smith P, Li J . Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics. 2010; 126(3):e687-92. PMC: 2932835. DOI: 10.1542/peds.2010-0098. View

18.

Zhou Q . [Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals]. Zhonghua Gan Zang Bing Za Zhi. 2015; 22(10):781-91. View

19.

Donohue J . A history of drug advertising: the evolving roles of consumers and consumer protection. Milbank Q. 2006; 84(4):659-99. PMC: 2690298. DOI: 10.1111/j.1468-0009.2006.00464.x. View

20.

Andersen D, BLANC W, CROZIER D, SILVERMAN W . A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956; 18(4):614-25. View